DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY

This adverse event was reported 254 times

These drugs are most commonly taken by patients reporting DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY:

# Drug Count
0 RITUXIMAB 155
1 CYCLOPHOSPHAMIDE 135
2 DOXORUBICIN 125
3 ETOPOSIDE 112
4 PREDNISONE 97
5 CISPLATIN 92
6 CYTARABINE 82
7 DEXAMETHASONE 80
8 DEXAMETHASONE 1.5 MG 79
9 IFOSFAMIDE 63
See all common drugs associated with DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY

DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 POLATUZUMAB VEDOTIN 46 0.0574
1 HYALURONIDASE (HUMAN RECOMBINANT) 1 0.0120
2 RITUXIMAB AND HYALURONIDASE 2 0.0087
3 IFOSFAMIDE 63 0.0057
4 CASPOFUNGIN ACETATE 13 0.0036
5 ETOPOSIDE 112 0.0030
6 DOXORUBICIN 125 0.0029
7 CYTARABINE 82 0.0025
8 SELINEXOR 5 0.0025
9 VINCRISTINE SULFATE 37 0.0023
See all drugs enriched for association with DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY

DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Endoglycosidase [EPC] 4 0.0055
1 Topoisomerase Inhibitor [EPC] 112 0.0028
2 Lipopeptide Antibacterial [EPC] 14 0.0016
3 CD20-directed Cytolytic Antibody [EPC] 159 0.0013
4 Platinum-based Drug [EPC] 146 0.0010
5 Alkylating Drug [EPC] 147 0.0010
6 CD30-directed Immunoconjugate [EPC] 4 0.0009
7 Nucleoside Metabolic Inhibitor [EPC] 82 0.0005
8 Corticosteroid [EPC] 175 0.0002
9 Vitamin K [EPC] 1 0.0002
See all drug classes enriched for association with DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY